Business Context and Reporting Period
This Form 8-K, dated August 26, 2022, is filed by Mana Capital Acquisition Corp. (the "Registrant") regarding a proposed Business Combination with Cardio Diagnostics, Inc. ("Cardio"). Under the terms of a Merger Agreement entered into on May 27, 2022, Mana Capital will merge with Cardio via a wholly-owned subsidiary. Upon completion, Mana Capital will change its name to Cardio Diagnostics Holdings, Inc., and Cardio will become a wholly-owned subsidiary.
Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for either Mana Capital or Cardio. This document serves as a disclosure of the transaction and the availability of an investor presentation rather than a financial results report.
Material Changes
The primary material change disclosed is the progression of the Business Combination. Mana Capital has filed a registration statement on Form S-4 containing proxy materials to solicit stockholder votes. An investor presentation regarding the transaction was made available on August 26, 2022, and is attached as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing contains extensive forward-looking statements regarding the anticipated financial impacts and future performance of the combined company. Management cautions that actual results may differ materially due to significant risks and uncertainties, including:
- Failure to satisfy closing conditions or obtain stockholder approval.
- Termination of the Merger Agreement.
- Inability to list the post-acquisition company on the Nasdaq Stock Market.
- Disruption of current plans and operations.
- Competition and the ability to grow profitably.
- Intellectual property protection risks.
- Impact of the COVID-19 pandemic.
The filing explicitly states it is not an offer to sell or a solicitation of an offer to buy securities.
Key Facts for Investor Verification
- Verify the terms of the Business Combination and the proposed name change to Cardio Diagnostics Holdings, Inc.
- Review the Form S-4 (File No. 333-265308) for detailed proxy materials and risk factors before voting.
- Examine the Investor Presentation (Exhibit 99.1) for management's projections, noting these are forward-looking and not filed for liability purposes.
- Confirm the status of regulatory approvals and stockholder voting requirements necessary to close the transaction.
- Check for any unsolicited offers or legal proceedings that could interfere with the merger.